The PennZone

WEST CHESTER, Pa., Aug. 25, 2021 /PRNewswire/ -- VESTECK, Inc., an early-stage medical device company, is pleased to announce its initial close on $4.3M of Series A financing, which includes conversion of all existing convertible notes.

The New World Angels (www.newworldangels.com) of S. Florida, led the Series A round with a $1.1 million investment.  The New Word Angels were joined by Florida-based DeepWork Capital and Ocean Azul Partners, as well as a number of Philadelphia-based investors, including Ben Franklin Technology Partners of Southeastern Pennsylvania, Robin Hood Ventures and the Delaware Crossing Investor Group. The Series A funds will support the manufacturing of products, pre-clinical testing and completion of in human procedures, prior to our clinical study for FDA clearance.

VESTECK has designed a platform technology comprised of 6 devices that integrate the delivery of nitinol sutures into a catheter, improving clinical outcomes for endovascular aortic aneurysm patients.

More on The PennZone

• Colonial Nissan Honors Serge Panchenko for 25 Years of Service
• New plusOne Research Finds the Orgasm Gap Is a 30-Point Chasm — and Confirms It Isn't Biology
• CCHR Report Links 145 Violent Incidents to Psychiatric Drug Exposure, Urges National Oversight and Action
• Best Companies Group Launches Free Best Accounting Firms to Work For Program
• Pittsburgh Practitioner Launches #1 Amazon Bestselling Book Built on Nobel Prize–Winning Science

The "Suture-Tight" catheter delivers nitinol sutures more easily than current endovascular or surgical options, securing endovascular aortic repair grafts to the aorta at initial implant or in repair procedures.  Dr. David H. Deaton, Chief Medical Officer, says, "the Suture-Tight catheter makes the process faster, easier and safer for surgeons and patients.  Suture-Tight will become the standard of care."  Vesteck expects to bring significant incremental revenue to an aortic repair market projected to be $4.5B by 2028.

VESTECK CEO Joe Rafferty stated, "We are truly honored that a consortium of such distinguished early-stage investors led by New World Angels believe in our plan, our team and our technology.  We are committed to proving their trust in us was accurate by helping solve this significant unmet need."

Commenting on the investment, Steve O'Hara, president of New World Angels, said, "We are delighted to support Joe Rafferty and his team at Vesteck as they seek to improve patient outcomes for a number of less invasive surgeries, starting with endovascular aortic repair procedures."

More on The PennZone

• Food Journal Magazine Unveils Its Latest 'Best of Los Angeles' Culinary Discoveries
• Boston Industrial Solutions Launches Natron® 717S Series: A New Flexible UV LED Ink for Ricoh GH2220 Printheads
• 5 Things NYC Courier Services Won't Tell You About How Same-Day Delivery Actually Works
• Tropidelic Links Up With International Reggae Star Collie Buddz and Eli Mac for Feel-Good Breakthrough Single "Follow Your Nature"
• Save 15 Percent on Florida Keys Accommodations with KeysCaribbean's 'Advance Purchase Rate Discount'

VESTECK was represented by Kevin M. Granahan of Fox Rothschild LLP.  The New World Angels were represented by Mark R. Mohler of Corridor Legal Partners, LLP.

About Vesteck Inc.:

VESTECK, Inc. (WWW.VESTECK.com) is an early-stage medical device company focused on bringing their proprietary technology to the aortic repair, structural heart and GI markets.

Their first product, the "Suture-Tight" nitinol suture delivery catheter will bring a novel technology to endovascular aortic repair market solving a significant global challenge for physicians and patients.

MEDIA CONTACTS:
New World Angels	VESTECK, Inc.
Sarah Lucas	Joe Rafferty
COO	CEO
(617) 894-5156	610-457-7324

SOURCE VESTECK, Inc.

Related Links

http://VESTECK.com

---

Show All News | Disclaimer | Report Violation